• 1. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

N-(4-Fluorobenzyl)-1-(3-Fluorophenyl)methanamine: A Comprehensive Overview

N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine (CAS No. 1019602-14-2) is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has been the subject of numerous studies aimed at understanding its potential applications in drug development and therapeutic interventions.

The molecular structure of N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine consists of a central methylene bridge connecting a 4-fluorobenzyl group and a 3-fluorophenyl group. The presence of fluorine atoms in both aromatic rings imparts distinct chemical and biological properties to the molecule, making it an intriguing candidate for various pharmacological investigations.

Recent research has highlighted the potential of N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine as a lead compound in the development of novel therapeutic agents. Studies have shown that this compound exhibits promising activity in modulating specific biological pathways, particularly those involved in neurodegenerative diseases and cancer. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine effectively inhibits the activity of certain kinases, which are key enzymes implicated in the progression of various cancers.

In addition to its potential anticancer properties, N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine has also been investigated for its neuroprotective effects. Research conducted at the University of California, San Francisco, revealed that this compound can reduce oxidative stress and inflammation in neuronal cells, suggesting its potential as a therapeutic agent for conditions such as Alzheimer's disease and Parkinson's disease.

The pharmacokinetic profile of N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine has been extensively studied to optimize its bioavailability and efficacy. Preclinical studies have shown that this compound exhibits favorable pharmacokinetic properties, including good oral bioavailability and a reasonable half-life, which are crucial for its potential use in clinical settings.

Furthermore, the safety profile of N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine has been evaluated in several preclinical models. Toxicity studies have indicated that this compound is well-tolerated at therapeutic doses, with no significant adverse effects observed. These findings support the continued exploration of N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine as a promising candidate for further clinical development.

The synthesis of N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine involves multi-step processes that require precise control over reaction conditions to ensure high yield and purity. Various synthetic routes have been reported in the literature, each with its own advantages and limitations. One commonly used method involves the coupling of 4-fluorobenzyl bromide with 3-fluoroaniline followed by reductive amination to form the final product. Advances in synthetic chemistry have led to more efficient and scalable methods for producing this compound, facilitating its broader application in research and development.

In conclusion, N-(4-Fluorobenzyl)-1-(3-fluorophenyl)methanamine (CAS No. 1019602-14-2) represents a promising molecule with diverse biological activities and potential therapeutic applications. Ongoing research continues to uncover new insights into its mechanisms of action and optimize its properties for clinical use. As our understanding of this compound deepens, it is likely to play an increasingly important role in the development of novel treatments for various diseases.

• 436086-79-2(Benzenemethanamine,3-fluoro-N-(phenylmethyl)-)
• 55096-88-3(benzyl(4-fluorophenyl)methylamine)
• 404-50-2(N-Benzyl-1-(4-fluorophenyl)-N-methylmethanamine)
• 162401-03-8(ethyl[(4-fluorophenyl)methyl]amine)
• 748124-46-1(3,4-Difluoro-N-methyl-benzylamine)
• 405-66-3(4-Fluoro-N-methylbenzylamine)
• 892596-78-0(N-(4-Fluorobenzyl)prop-2-yn-1-amine)
• 90389-87-0(N-(3-Fluorobenzyl)propan-2-amine Hydrochloride)
• 90389-86-9(N-(3-Fluorobenzyl)propylamine)
• 90389-85-8(N-Ethyl-3-fluorobenzylamine)